On Jan 5, 2022, Revelar Biotherapeutics and Twist Bioscience announced that RBT-0813 binded to and neutralized the Omicron and Delta variants of SARS-CoV-2 in live virus studies.

RBT-0813 is an innovative bispecific antibody discovered by Twist Biopharma and licensed to Revelar Biotherapeutics that targets epitopes on the SARS-CoV-2 spike protein. Revelar continued to advance preclinical development of RBT-0813 to submit an Investigational New Drug application in the first half of 2022 to begin human clinical trials shortly thereafter.